{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.48","value":"49.90"},{"groupId":"OG001","spread":"1.26","value":"47.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Overall survival defined as time from first treatment of MMY, i.e. day of first dose of induction therapy for MMY to date of death","dispersionType":"Standard Error","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEDIAN","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}